Corvus Pharmaceuticals Inc Stock
Corvus Pharmaceuticals Inc shows a slight decrease today, losing -€0.020 (-0.170%) compared to yesterday.
We see a rather positive sentiment for Corvus Pharmaceuticals Inc with 7 Buy predictions and 1 Sell predictions.
With a target price of 27 € there is potential for a 130.97% increase which would mean more than doubling the current price of 11.69 € for Corvus Pharmaceuticals Inc.
Our community identified positive and negative aspects for Corvus Pharmaceuticals Inc stock for the coming years. 6 users see the criterium "Worthwhile Investment for the next years" as a plus for the Corvus Pharmaceuticals Inc stock. On the other hand our users think that "General Risks" could be a problem in the future.
Pros and Cons of Corvus Pharmaceuticals Inc in the next few years
Pros
?
M***** P*******
?
S********** s********
?
G***** c******* t* c**********
Cons
?
W********* I********* f** t** n*** y****
?
B****
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Corvus Pharmaceuticals Inc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Corvus Pharmaceuticals Inc | -0.170% | 6.369% | -9.660% | 225.174% | 88.853% | 496.429% | 604.217% |
| Evolus Inc | 2.620% | 5.140% | -10.131% | 4.419% | 0.587% | -38.404% | -43.485% |
| Heron Therapeutics Inc. | -1.610% | -0.093% | 14.255% | -72.306% | -61.293% | -71.444% | -95.712% |
| Rhythm Pharmaceuticals | -1.050% | 3.279% | -1.563% | 24.342% | 1.070% | 333.486% | 707.692% |
Comments
Corvus Pharmaceuticals (CRVS) is now covered by The Goldman Sachs Group, Inc.. They set a "buy" rating on the stock.
Show more
Ratings data for CRVS provided by MarketBeat
Corvus Pharmaceuticals (CRVS) had its "outperform" rating reaffirmed by Oppenheimer Holdings, Inc.. They now have a $33.00 price target on the stock, up from $32.00.
Show more
Ratings data for CRVS provided by MarketBeat
Corvus Pharmaceuticals (NASDAQ:CRVS) had its "buy" rating reaffirmed by analysts at Jefferies Financial Group Inc..
Show more
Ratings data for CRVS provided by MarketBeat
News
Corvus Pharmaceuticals Q2 Earnings Call Highlights
Key Points
- Interested in Corvus Pharmaceuticals, Inc.? Here are five stocks we like better.
- Corvus reported a wider Q2 loss as research and development spending rose to $16 million for
Corvus Pharmaceuticals Director Buys 21,700 Shares. Does This Mean CRVS a Buy?
Immuno-oncology specialist Corvus Pharmaceuticals (NASDAQ:CRVS) reported a recent insider buy amid a year of sharp share price gains.
On June 11, 2026, David Scott Moore, acquired the direct
Boxer Capital’s $18 Million Corvus Pharma Bet Signals Confidence in This Biotech’s Next Phase
On May 15, 2026, Boxer Capital Management disclosed a new position in Corvus Pharmaceuticals (NASDAQ:CRVS), acquiring 1,100,000 shares in the first quarter for an estimated $17.55 million based on